The Evolving Role of Immunotherapy in Early Stage & Advanced/Metastatic Triple Negative Breast Cancer

April 21, 2021

This presentation will examine the evolving role of immunotherapy in early stage and advanced/metastatic triple negative breast cancer including the evidence for regimens in the management of each as well as current biomarkers.

Learning Objectives

  • Examine the evidence for immunotherapy regimens in the management of early stage Triple Negative Breast Cancer
  • Examine the evidence for immunotherapy regimens in the management of advanced stage Triple Negative Breast Cancer
  • Examine the current biomarkers in breast cancer predicting immunotherapy efficacy
Course summary
Available credit: 
  • 1.00 ACPE - Pharmacist
  • 1.00 AMA PRA Category 1 Credit(s)
  • 1.00 ANCC
  • 1.00 Attendance
  • 1.00 JA Credit - AH
    • 1.00 Approved for AMA PRA Category 1 Credit(s)
Registration Opens: 
04/21/2021
Registration Expires: 
04/20/2022
Activity Starts: 
04/21/2021 - 4:00pm EDT
Activity Ends: 
04/21/2021 - 5:00pm EDT
Rating: 
0

Available Credit

  • 1.00 ACPE - Pharmacist
  • 1.00 AMA PRA Category 1 Credit(s)
  • 1.00 ANCC
  • 1.00 Attendance
  • 1.00 JA Credit - AH
    • 1.00 Approved for AMA PRA Category 1 Credit(s)
Please login or register to take this course.